Bio-Rad

As previously disclosed, Bio-Rad's accounting firm needs more time to complete its audit and the company plans to file the form as soon as possible.

The GenomeWeb Index outperformed the Nasdaq Biotechnology Index, which lost 5 percent in February, but lost the same amount as the Dow.

The firm saw an increase in sales for both the life science and clinical diagnostics segments.

The firm has provided glimpses into its strategies for developing a line of regulated droplet digital PCR tests in a number of recent forums.

Some of the biggest players in the life science tools and diagnostics industries including Danaher, Agilent, and Hologic presented on day two of the conference, discussing plans for 2018.

The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.

The agreement, with Genetic Analysis of Oslo, involves technology to detect gut dysbiosis and investment for additional tests.

The test uses droplet digital PCR to detect BCR-ABL gene fusions and is intended for treatment response monitoring of chronic myeloid leukemia.

The Index significantly outperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index as it showed double the growth that it had displayed in October.

Pages

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.